sur Theranexus (EPA:ALTHX)
THX Pharma appoints Julien Veys as Deputy General Manager
On January 7, 2026, THX Pharma, a company specializing in rare neurological diseases, announced the appointment of Julien Veys as Deputy Chief Executive Officer. This decision supports the company's new strategy focused on the international commercialization of drugs such as TX01 and Batten-1.
Mathieu Charvériat, CEO of THX Pharma, highlights Veys' expertise in strategic development as a valuable asset for the company. Veys expresses its satisfaction in contributing to the company's evolution towards the commercialization of innovative therapies.
Veys, a key member of the company since 2016, has been involved in crucial milestones such as Theranexus's IPO and strategic agreements. Previously, he played a significant role at Trophos, notably during its acquisition by Roche.
R. P.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Theranexus